Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Circulating Free RNA as a Therapeutic Evaluation in Diffuse Large B-cell Lymphoma: A Case Series from the Indonesian Cancer Center

ACTA MEDICA INDONESIANA · Vol. 56 No. 4 (2025)

ISSN
2338-2732, 0125-9326
Terbit
2025-01-21
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Cancer is still the leading cause of death worldwide. Despite advances in diagnosis, management with the rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) chemotherapy regimen, and careful clinical and radiologic evaluation, diffuse large B-cell lymphoma (DLBCL) still carries high recurrence in clinical practice. This case series aims to assess the potential of circulating free RNA as a biomarker for evaluating therapeutic responses in DLBCL. This case series was conducted at Dharmais National Cancer Center Hospital in Jakarta in 2020. The subjects were 13 DLBCL patients who came for treatment to our hospital in 2020. Sampling was carried out by taking peripheral blood, which was taken 7–14 days after the patient underwent the 3rd and 6th cycles of chemotherapy or before and 7–14 days following the 3rd cycle of chemotherapy. Circulating free RNA (cfRNA) was extracted and assessed. The quantity of cfRNA was subsequently examined twice as matching samples from each patient, with the following results – (1) no mutations detected; (2) mutation detected solely in the second examination; (3) mutation only detected in the first examination; and (4) changes in gene mutations and mutation types. Statistic tabulation neither showed an association between recurrency and clinical variables nor detected cfRNA from the matching samples. This case series underscores the challenges in utilizing cfRNA as a biomarker for therapeutic evaluation in DLBCL due to heterogeneity and increased mutations in post chemotherapy conditions. Further research with larger sample sizes is needed to emphasize the role of cfRNA in DLBCL disease monitoring.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 200 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • State University of Semarang
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Hamzah ShatriAfiliasi tidak diketahui8
Cleopas Martin RumendeAfiliasi tidak diketahui5
Siti SetiatiAfiliasi tidak diketahui4
Robert SintoAfiliasi tidak diketahui4
Rudi PutrantoAfiliasi tidak diketahui3
Irsan HasanAfiliasi tidak diketahui3
Murdani AbdullahAfiliasi tidak diketahui3
Alvina WidhaniAfiliasi tidak diketahui3
Andhika RachmanAfiliasi tidak diketahui2
Lugyanti SukrismanAfiliasi tidak diketahui2
Muhadi MuhadiAfiliasi tidak diketahui2
Dadang MakmunAfiliasi tidak diketahui2
Juferdy KurniawanAfiliasi tidak diketahui2
Rudy HidayatAfiliasi tidak diketahui2
Pringgodigdo NugrohoAfiliasi tidak diketahui2
Chyntia Olivia Maurine JasirwanAfiliasi tidak diketahui2
Khie Chen LieAfiliasi tidak diketahui2
Suryo Anggoro Kusumo WibowoAfiliasi tidak diketahui2
Erni Juwita NelwanAfiliasi tidak diketahui2
Noto DwimartutieAfiliasi tidak diketahui2
Sally Aman NasutionAfiliasi tidak diketahui2
Arini SetiawatiAfiliasi tidak diketahui1
T. Djumhana AtmakusumaAfiliasi tidak diketahui1
Karmel L TambunanAfiliasi tidak diketahui1
Shufrie EffendiAfiliasi tidak diketahui1
Eddy SuratmanAfiliasi tidak diketahui1
Anastasia PutriState University of Semarang1
Melva LouisaAfiliasi tidak diketahui1
Soekamto KoesnoeAfiliasi tidak diketahui1
Arif MansjoerAfiliasi tidak diketahui1
Rasco Sandy SihombingAfiliasi tidak diketahui1
Sri Agustini KurniawatiAfiliasi tidak diketahui1
Nia Novianti SiregarAfiliasi tidak diketahui1
Nina Kemala SariAfiliasi tidak diketahui1
Rensa RensaAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Circulating Free RNA as a Therapeutic Evaluation in Diffuse Large B-cell Lymphoma: A Case Series from the Indonesian Cancer Center</dc:title>
	<dc:creator>Sutandyo, Noorwati</dc:creator>
	<dc:creator>Rinaldi, Ikhwan</dc:creator>
	<dc:creator>Setiawan, Lyana</dc:creator>
	<dc:creator>Sugiarto, Christine</dc:creator>
	<dc:creator>Prayitno, Yuniar Harris</dc:creator>
	<dc:subject xml:lang="en-US">circulating free RNA</dc:subject>
	<dc:subject xml:lang="en-US">DLBCL</dc:subject>
	<dc:subject xml:lang="en-US">therapeutic evaluation</dc:subject>
	<dc:subject xml:lang="en-US">lymphoma</dc:subject>
	<dc:subject xml:lang="en-US">NGS</dc:subject>
	<dc:subject xml:lang="en-US">internal medicine</dc:subject>
	<dc:subject xml:lang="en-US">hematology</dc:subject>
	<dc:subject xml:lang="en-US">oncology</dc:subject>
	<dc:description xml:lang="en-US">Cancer is still the leading cause of death worldwide. Despite advances in diagnosis, management with the rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) chemotherapy regimen, and careful clinical and radiologic evaluation, diffuse large B-cell lymphoma (DLBCL) still carries high recurrence in clinical practice. This case series aims to assess the potential of circulating free RNA as a biomarker for evaluating therapeutic responses in DLBCL. This case series was conducted at Dharmais National Cancer Center Hospital in Jakarta in 2020. The subjects were 13 DLBCL patients who came for treatment to our hospital in 2020. Sampling was carried out by taking peripheral blood, which was taken 7–14 days after the patient underwent the 3rd and 6th cycles of chemotherapy or before and 7–14 days following the 3rd cycle of chemotherapy. Circulating free RNA (cfRNA) was extracted and assessed. The quantity of cfRNA was subsequently examined twice as matching samples from each patient, with the following results – (1) no mutations detected; (2) mutation detected solely in the second examination; (3) mutation only detected in the first examination; and (4) changes in gene mutations and mutation types. Statistic tabulation neither showed an association between recurrency and clinical variables nor detected cfRNA from the matching samples. This case series underscores the challenges in utilizing cfRNA as a biomarker for therapeutic evaluation in DLBCL due to heterogeneity and increased mutations in post chemotherapy conditions. Further research with larger sample sizes is needed to emphasize the role of cfRNA in DLBCL disease monitoring.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2025-01-21</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2529</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 56 No. 4 (2024): Acta Medica Indonesiana; 507</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2529/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2025 Noorwati Sutandyo, Ikhwan Rinaldi, Lyana Setiawan, Christine Sugiarto, Yuniar Harris Prayitno</dc:rights>
</oai_dc:dc>